Lumify®
Brimonidine 0.025% · ophthalmic solution
Aesthetics/Presbyopia
Approved uses
Ocular redness from minor eye irritation
1 drop in the affected eye(s) every 6 to 8 hours, maximum 4 times daily
Redness is reduced for 8 hours, with no tachyphylaxis or rebound through 29 days of use.
Contraindications
- Do not use if the solution changes color or becomes cloudy
- The label gives no other condition under which the drops must not be used
Ophthalmic solution, 0.025% (0.25 mg/mL), 2.5 mL, 3.5 mL, 5 mL, 7.5 mL dropper bottles; 0.4 mL ampules
Highly selective alpha-2 adrenergic receptor agonist producing conjunctival vasoconstriction and blanching. Alpha-2 selectivity is the point of difference from the alpha-1 and mixed alpha-1/alpha-2 decongestants (phenylephrine, tetrahydrozoline, naphazoline, oxymetazoline), which are associated with tachyphylaxis and rebound redness.
Warnings & Precautions
- Stop use and ask a doctor: If you experience eye pain, changes in vision, or continued redness or irritation of the eye, or if the condition worsens or persists for more than 3 days.
- External use only: The label states the drops are for external use only.
- Keep out of reach of children: If swallowed, get medical help or contact a Poison Control Center right away.
- Contamination: To avoid contamination, do not touch tip of container to any surface; replace cap after each use.
- Scotopic miosis: In 28 healthy adult volunteers measured before and after instillation, average scotopic pupil size fell from 7.28 mm to 6.36 mm 60 min after instillation, with a greater effect in light irides than dark irides (1.55 mm vs. 0.67 mm). The authors state further studies are needed to determine whether the amount of miosis is clinically significant.
Common Side Effects
- Ocular: In pooled trial safety data (426 treated, 209 vehicle), reduced visual acuity 4.0% and conjunctival hyperemia 2.6%, both at vehicle rates (4.3% and 2.9%).
- Systemic: Not characterized; this OTC label has no adverse reactions section and the pooled analysis reported ocular events.
Pregnancy: If pregnant, ask a health professional before use.
Lactation: If breast-feeding, ask a health professional before use.
Labeled for age 5 years and over; under 5, the label directs consultation.